Payment overview · 2025
General Payments
$1,727.31
88 reported records · 24 companies
Healthcare provider profile · identity verified
Richard Michael Kastelic, MD
Allopathic & Osteopathic Physicians|Family Medicine · JOHNSTOWN, PA · NPI 1548265986
Verified facts
What the public records show
CMS Open Payments records show Richard Michael Kastelic, MD received $1,727.31 in general payments during 2025 across 88 reported records.
PFIZER INC. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 466 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 466 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $313.63 | 18.2% | 18 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $229.00 | 13.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.56 | 8.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.13 | 8.3% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $141.85 | 8.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.68 | 7.8% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $99.23 | 5.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $73.36 | 4.2% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $69.33 | 4.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.19 | 3.4% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.00 | 2.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.34 | 1.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.55 | 1.6% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $28.01 | 1.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.51 | 1.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.26 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.19 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.90 | 1.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.73 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $19.44 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.29 | 1.1% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $17.76 | 1.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.98 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.39 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,707.09 | 87 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $236.93 | 14 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $229.00 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $229.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $166.82 | 9 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $141.85 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $135.68 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $99.23 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $96.85 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $77.46 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $76.70 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $76.70 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $76.70 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $73.36 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.24 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.19 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.19 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.54 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.28 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.28 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 466 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 144 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
116 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
466 | 83 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
144 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
466 | 83 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 953 | 266 |
| Atorvastatin Calcium | Atorvastatin Calcium | 729 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 677 | 168 |
| Pantoprazole Sodium | Pantoprazole Sodium | 644 | 162 |
| Pravastatin Sodium | Pravastatin Sodium | 638 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 594 | 134 |
| Metformin Hcl | Metformin Hcl | 523 | 139 |
| Simvastatin | Simvastatin | 501 | 117 |
| Eliquis | Apixaban | 466 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 466 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 424 | 130 |
| Furosemide | Furosemide | 356 | 88 |
| Escitalopram Oxalate | Escitalopram Oxalate | 330 | 90 |
| Potassium Chloride | Potassium Chloride | 300 | 71 |
| Lorazepam | Lorazepam | 279 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 77 |
| Sertraline Hcl | Sertraline Hcl | 259 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 68 |
| Omeprazole | Omeprazole | 252 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 250 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 246 | 69 |
| Losartan Potassium | Losartan Potassium | 223 | 57 |
| Atenolol | Atenolol | 222 | 56 |
| Allopurinol | Allopurinol | 219 | 53 |
| Montelukast Sodium | Montelukast Sodium | 195 | 35 |
| Gabapentin | Gabapentin | 185 | 49 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 178 | 44 |
| Donepezil Hcl | Donepezil Hcl | 169 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 144 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 22 |
| Synthroid | Levothyroxine Sodium | 116 | 31 |
| Warfarin Sodium | Warfarin Sodium | 114 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 107 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 23 |
| Prednisone | Prednisone | 103 | 42 |
| Alprazolam | Alprazolam | 102 | 19 |
| Tradjenta | Linagliptin | 96 | 23 |
| Ezetimibe | Ezetimibe | 94 | 19 |
| Ozempic | Semaglutide | 94 | 15 |
| Finasteride | Finasteride | 89 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 88 | 26 |
| Clonazepam | Clonazepam | 84 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 84 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | 20 |
| Tramadol Hcl | Tramadol Hcl | 80 | 19 |
| Famotidine | Famotidine | 79 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 76 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 18 |
| Jardiance | Empagliflozin | 72 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 28 |
| Glipizide | Glipizide | 67 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 29 |
| Celecoxib | Celecoxib | 63 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 60 | 13 |
| Diazepam | Diazepam | 60 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 15 |
| Alendronate Sodium | Alendronate Sodium | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 32 |
| Carvedilol | Carvedilol | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 18 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 13 |
| Buspirone Hcl | Buspirone Hcl | 49 | 14 |
| Mirtazapine | Mirtazapine | 49 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 14 |
| Spironolactone | Spironolactone | 47 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Meloxicam | Meloxicam | 45 | 14 |
| Glipizide Er | Glipizide | 44 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | 11 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Repatha Syringe | Evolocumab | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 11 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Latanoprost | Latanoprost | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Constulose | Lactulose | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 22 | 22 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Felodipine Er | Felodipine | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Dilantin | Phenytoin Sodium Extended | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Mesalamine Er | Mesalamine | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | 11 |
| Humalog | Insulin Lispro | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 14 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Insupen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Dipentum | Olsalazine Sodium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Apri | Desogestrel-Ethinyl Estradiol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tegretol | Carbamazepine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,727.31 · 88 records | PFIZER INC. | ABRYSVO, AREXVY, CAPVAXIVE, CLOTTRIEVER BOLD CATHETER, COMIRNATY, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, FREESTYLE LIBRE 3, Flexitouch Plus, Fluad, Flucelvax, GARDASIL 9, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Nimbl, OFEV, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, WATCHMAN FLX, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error